5.52
-0.14(-2.47%)
Currency In USD
| Previous Close | 5.66 |
| Open | 5.66 |
| Day High | 5.66 |
| Day Low | 5.32 |
| 52-Week High | 5.78 |
| 52-Week Low | 1.84 |
| Volume | 454,002 |
| Average Volume | 1.22M |
| Market Cap | 293.79M |
| PE | -4.09 |
| EPS | -1.35 |
| Moving Average 50 Days | 4.68 |
| Moving Average 200 Days | 3.38 |
| Change | -0.14 |
If you invested $1000 in Achieve Life Sciences, Inc. (ACHV) 10 years ago, it would be worth $3.53 as of January 14, 2026 at a share price of $5.52. Whereas If you bought $1000 worth of Achieve Life Sciences, Inc. (ACHV) shares 5 years ago, it would be worth $607.26 as of January 14, 2026 at a share price of $5.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer
GlobeNewswire Inc.
Jan 12, 2026 1:47 PM GMT
Experienced medical executive advances to permanent role following successful leadership as Interim CMOSEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pha
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
GlobeNewswire Inc.
Dec 08, 2025 9:10 PM GMT
SEATTLE and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treat
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation
GlobeNewswire Inc.
Nov 03, 2025 1:30 PM GMT
120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Achi